Trial Profile

A Phase Ib, Single- and Multiple-Dose, Open-Label Study of The Safety, Pharmacokinetics and Pharmacodynamics of Obinutuzumab in Adults With End-Stage Renal Disease and Hypersensitization Awaiting Renal Transplantation

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Obinutuzumab (Primary) ; Immune globulin
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Lupus nephritis; Non-Hodgkin's lymphoma
Focus Adverse reactions
Sponsors Roche

01 Jul 2019 Results assessing safety, pharmacokinetics, and pharmacodynamic activity of obinutuzumab, published in the American Journal of Transplantation.
02 Jan 2019 Status changed from active, no longer recruiting to completed.
29 Oct 2018 Planned End Date changed from 5 Dec 2018 to 27 Nov 2018.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com